In the acute promyelocytic leukemia cell line, NB4, activation of the CD44 receptor triggers apoptosis. This pathway does not operate in the retinoid-maturation-resistant NB4-LR1 subclone. In this work, we show that the CD44 gene is silenced in these cells. The molecular defect involves DNA methylation of cytosine phosphate guanine (CpG) island and underacetylation of histone H3 at CD44 promoter. The methylating inhibitor 5-aza-CdR and cyclic AMP (cAMP) reverse the CD44 gene silencing. Contrary to 5-aza-CdR, cAMP does not induce DNA demethylation or histone modification at the CD44 promoter, whereas an H3pS10/AcK14 dual modification is observed on a global level. cAMP also induces the expression of c-Jun transcription factor and its recruitment at the CD44 promoter. Chromatin immunoprecipitation assays further show the association of brahma (Brm), a subunit of SWI/SNF chromatinremodelling complex involved in the crosstalk between transcription and RNA polymerase II (RNA Pol II) processing, as well as the binding of phosphorylated RNA Pol II to the proximal promoter region of CD44. Finally, our study reveals that cAMP re-establishes the CD44-mediated cell death signalling. We propose that one of the actions of cAMP in restoring normal cell phenotype of leukaemia cells may consist in a broad trans-reactivation of silenced genes, despite marked hypermethylation of their promoters, as illustrated here with CD44 re-expression.
Introduction
CD44 is a multifunctional cell surface molecule differentially expressed, via various alternative spliced isoforms 1 in many cell types. 2, 3 These surface molecules are involved in a fascinating number of distinct functions, including cell proliferation, cell survival, differentiation, cell adhesion and migration, angiogenesis. [4] [5] [6] While CD44 is important for the physiological behaviour of normal cells, it has rapidly been recognized that altered CD44 expression participates in the initiation or progression of tumour cells towards transformed phenotypes and metastasis. Importantly, in the case of myeloid leukaemia, 7, 8 targeting CD44 by means of epitope-specific antibodies, cells undergo maturation and/or apoptosis, with anti-tumour features that can be exploited therapeutically.
In acute promyelocytic leukaemias (APL), all-trans retinoic acid (ATRA) induces the differentiation of leukemic cells, leading to remission of the disease. This differentiation therapy is however not durable and ATRA resistance often develops. It has been recently reported that in the APL cell model, NB4, 9 anti-CD44 antibodies triggered growth inhibition and cell death. 8, 10, 11 This feature is of clinical importance for APL cells and CD44 signalling could in particular represent an alternative therapeutic approach for ATRA-resistant APL cells. 12, 13 These cells fail to be growth inhibited and do not mature during retinoid treatment. Very likely, they bear secondarily acquired alterations, which have been lastly shown to be overcome by cyclic AMP (cAMP)-dependent signallings. This is typically the case exemplified in vitro by the ATRA-resistant subclone NB4-LR1 cells, which requires a combined cAMP/ATRA treatment to undergo differentiation and cell death. [14] [15] [16] The additional defects present in these resistant cells, as well as the molecular mechanism(s) by which cAMP acts to normalize the NB4-LR1 cell phenotype, are still poorly understood, although several proposals supported by independent investigations have been recently forwarded. [17] [18] [19] [20] [21] In this study, we demonstrate that there is an altered CD44 gene expression in the ATRA-maturation-resistant NB4-LR1 cells, and characterize the molecular defects behind this lack of CD44 receptor expression as DNA methylation of the CD44 promoter and deacetylation of histones at this locus. Importantly, full reactivation of CD44 gene transcription and synthesis of a functional CD44 receptor protein were rapidly obtained with a DNA methylating inhibitor (5-aza-CdR). Epigenetic events have been reported to be involved in downregulation of genes responsible for drug resistance in cancer cells. 22, 23 Interestingly, we show here that cAMP treatment of NB4-LR1 cells reverses CD44 transcription silencing and restores the expression of a functional CD44 receptor, able again to trigger cell death in response to the specific A3D8 anti-CD44 antibody. Given the diverse cellular cAMP effects that, collectively, could contribute to the rescue of the ATRA-maturation program in NB4-resistant cells, we speculate that a broad modification of the chromatin transcription context by PKA signalling could render resistant cells competent for further commitment towards more than a single biological response (for example, cell differentiation, growth arrest, cell death).
Materials and methods

Reagents
ATRA, 8-(4-chlorophenylthio)-cAMP (8-CPT-cAMP), 5-aza-2
0 -deoxycytidine (5-aza-CdR) and trichostatin A (TSA) were purchased from Sigma (St Quentin Fallavier, France).
Cell lines
NB4 and NB4-LR1 cell lines 16 were routinely cultured in RPMI 1640 medium (Invitrogen, Carlsbad, CA, USA) supplemented with 2 mM L-glutamine, 100 U per milliliter penicillin (Invitrogen), 0.1 mg ml À1 streptomycin (Invitrogen) and 10% fetal calf serum (Invitrogen, Carlsbad, CA, USA). Cells were grown at 37 1C in a 5% CO 2 atmosphere.
CD44 protein expression in NB4 and NB4-LR1 cells by immunofluorescence and flow cytometry analysis NB4 and NB4-LR1 cells were incubated with an anti-CD44 antibody against an epitope of the standard form (clone J173 or A3D8), or the isotype-matched non-specific mouse immunoglobulin G (IgGs), and Alexa 488-conjugated secondary antibodies (fluorescein isothiocyanate, FITC; Dako, Trappes, France), in the presence of Texas Red-labelled phalloidin to visualize the actin filaments. Confocal laser scanning microscopy analysis was performed using a Biorad MRC1024 confocal imaging system (UK). Immunofluorescent cells were also analysed by flow cytometry on a FACSCalibur instrument (Becton Dickinson Immunocytometry Systems, de Pont-De-Claix, France) using CellQuest software. Results were expressed as histograms of FITC staining (fluorescence intensity) and quantified as the relative mean fluorescence intensity compared with isotype control antibodies. Representative histograms represent an acquisition of 10 4 events.
RT-PCR analysis
Total RNAs purified from NB4 and NB4-LR1 cells, exposed or not to 1 mM ATRA or 100 mM 8-CPT-cAMP, for 96 h or 72 h, respectively, were isolated using the RNeasy Kit (Qiagen), and were reversed transcribed by using 200 U MMLV reverse transcriptase enzyme (Promega). PCR amplification of CD44 transcripts was then performed with primers specific for the 5 0 -and 3 0 -constant region of CD44, that is, forward primer (in exon 5): 5 0 -TTGTTAACCGTGATGGCACC-3 0 and reverse primer (in exon 16): 5 0 -ATTTGGGGTGTCCTTATAG-3 0 . The PCR reaction was performed for 30 cycles of denaturation at 95 1C for 45 s, annealing at 52 1C for 60 s, and extension at 72 1C for 75 s, followed by 72 1C for 15 min, using 2.5 U of Ampli taq polymerase. c-jun and brm transcripts were detected by using the following primers: c-jun, forward primer 5 0 -GACTGCAAAG ATGGAAACGA-3 0 and reverse primer 5 0 -GTTGCTGGACTGGA TTATCA-3 0 (253 bp product), brm, forward primer 5 0 -CCAGTA GGCAGGAAACCGAAG-3 0 and reverse primer 5 0 -GGCTTGCAT ATGGCGATACA-3 0 (1 kb product). PCR reactions were run at 94 1C for 30 s, 56 1C for 1 min and 72 1C for 1 min with 29 cycles, followed by 10 min at 72 1C. Primers specific for glyceraldehyde-3-phosphate dehydrogenase (GAPDH) gene were used for loading controls: 5 0 -CTCAGACACCATGGGG AAGGTGA-3 0 (forward) and 5 0 -ATGATCTTGAGGCTGTTGT CATA-3 0 (reverse).
Restriction enzyme digestion and PCR analysis for CD44 methylation
Promoter methylation of CD44 gene was determined by methylation-sensitive restriction enzyme digestion followed by PCR analysis, as described elsewhere with some modifications. 24 Three restriction enzymes exhibiting complementary methylation sensitivity were used: the methylation-sensitive restriction enzyme HpaII, its methylation-insensitive isoschizomer MspI (control), both acting at CCGG sites, as well as McrBC, a restriction enzyme that cleaves only methylated DNA (in contrast to HpaII) at G/A m cytosines. Of note, this restriction enzyme cannot digest the C m CGG HpaII specific sites. PCRs of the digested genomic DNA were then performed using advantage-guanine-cytosine (GC) genomic PCR Kit (Clontech, St Germain-en-Laye, France) in a total volume of 20 ml with 1 M GC melt, 25 pmol of each primer, 0.2 mM desoxyribonucleotide triphosphates (dNTPs), restriction enzyme-digested DNAs (250 ng) and 2.5 U of advantage Tth polymerase. Amplification was carried out on a thermocycler for 94 1C for 45 s, 63 1C for 2 min and 72 1C for 2 min for 37 cycles, followed by 72 1C for 15 min. Primers were designed according to the published sequence of the 5 0 region of CD44: forward, 5 0 -CTCCCCACCC CTCACTCC-3 0 and reverse, 5 0 -CCCCGCACCCATCTTGCTG-3 0 . These primers cover the cytosine phosphate guanine (CpG)-rich promoter and exon 1 regions (total of 44 CpG sites), yielding a 777 bp product, which corresponds to position À668 to þ 109 relative to the translation initiation site. A 20 ml portion of PCR product was loaded on 2% agarose gel, stained with ethidium bromide and scanned using Biomax image analysis software.
5-Aza-CdR treatment of NB4-LR1 cells
Exponentially growing NB4-LR1 cells were exposed to the methylating inhibitor agent, 5-aza-CdR, at a concentration of 100-250 nM. Cells were mock treated with an identical volume of dimethyl sulfoxide.
Pyrosequencing assay
Genomic DNAs, isolated from NB4 and NB4-LR1 cells, stimulated or not with 8-CPT-cAMP (100 mM) or with 5-aza-CdR (250 nM), were sodium bisulphite treated with the EZ-96 DNA methylation kit (ZymedResearch, San Francisco, CA, USA). To analyse and quantify the degree of DNA methylation within CD44 promoter, a 541 bp-modified DNA fragment, covering 41 CpG sites and corresponding to position À541 to þ 1 (relative to the translation initiation site), was amplified and pyrosequenced by Biotage BA (Uppsala, Sweden). Percentages of DNA methylation (proportions of methylated alleles) at each individual CpG site were determined.
ChIP assays and PCR
Chromatin immunoprecipitation assays (ChIPs) were performed on growing NB4 and NB4-LR1 cells, treated or not with 8-CPTcAMP, by using the ChIP assay kit from Upstate Biotechnology (Lake Placid, NY, USA) for histone immunoprecipitations and the ChIP-IT kit from Active Motif (Rixensart, Belgium) for c-Jun, Brm and RNA polymerase II (RNA Pol II) immunoprecipitations, according to the manufacturer's instructions. Briefly, cells were cross-linked with 1% formaldehyde, lysed and sonicated to obtain 0.6-to 0.8-kbp genomic DNA. Equal aliquots of the precleared chromatin lysates were then incubated with preimmune or no antibody (as negative control), with antibodies to modified histone H3 and H4 (Upstate Biotechnology) as indicated, or to c-Jun (Active Motif), to Brm (N-19) (Santa Cruz, CA, USA) and to a phosphorylated form of RNA Pol II (serine 5 phosphorylation of the C-terminal domain; Active Motif) at 4 1C overnight. To study the DNA/histone complexes, the immunoprecipitated (IP) DNA samples and the input DNA (total chromatin) were amplified using two pairs of primers that cover two different 100 bp regions within the CD44 promoter: (1) 0 -GCCACCAAAACTTGTCCATG-3 0 (297 bp product, encompassing the transcription start site and corresponding to position À278 to þ 19, relative to the translation initiation site). Amplifications were carried out at 94 1C for 30 s, 56 1C (for c-Jun and RNA Pol II) or 68 1C (for Brm) for 30 s and 72 1C for 30 s for 29 cycles, followed by 72 1C for 10 min. As a negative control for c-Jun and Brm ChIP assays, a distal promoter region of the housekeeping GAPDH gene was PCR amplified, using the following primers: forward primer, 5
0 -TCCT GTTTCATCCAAGCGTG-3 0 and reverse primer, 5 0 -GACTGTCG AACAGGAGGAG-3 0 with an annealing temperature at 60 1C, whereas negative primers provided by Active Motif were used as negative control for RNA Pol II ChIP assays: forward primer, 5 0 -ATGGTTGCCACTGGGGATCT-3 0 and reverse primer, 5 0 -TGCCAAAGCCTAGGGGAAGA-3 0 . PCR products were loaded on 2% agarose gel, stained with ethidium bromide and scanned using Biomax image analysis software.
Western blot analysis
Exponentially growing NB4 or NB4-LR1 cells were exposed to ATRA (1 mM), 8-CPT-cAMP (100 mM) or to adequate vehicle, as indicated. Cells were lysed in Laemmli buffer and samples were resolved by SDS-PAGE on 10-20% polyacrylamide gels for analysis of histones, or on 10% polyacrylamide gels for analyses of CD44, c-Jun or Brm, and electrotransferred onto 0.2 mm nitrocellulose membrane sheets (BA85, Whatman Schleicher & Schuell, Dassel, Germany). Membranes were then probed with the appropriate specific antibodies to modified histones (Upstate Biotechnology), to c-Jun (sc-45, Santa Cruz), to p-c-Jun(Ser63/ 73) (sc-16312, Santa Cruz) or to Brm (N-19, Santa Cruz), as indicated. Anti-mouse, anti-rabbit or anti-goat IgGs, conjugated to horse peroxidase (Dako) were used as secondary antibodies, and immunoreactive bands were revealed by a chemiluminescence detection kit (ECL, Amersham, Buckinghamshire, UK). Immunoblots were further scanned to quantify band intensities using Biomax image analysis software.
Morphology and DAPI analysis of NB4-LR1 cells in response to A3D8 anti-CD44 antibody
Exponentially growing NB4-LR1 cells were exposed to 8-CPT-cAMP (100 mM) or to adequate vehicle, for 48 h. 8-CPT-cAMP-primed cells were then further treated either with 8-CPT-cAMP alone or in co-treatment with A3D8 anti-CD44 antibody (Sigma) at a concentration of 2 mg ml À1 for 96 h. As control, mocked NB4-LR1 were also treated with the A3D8 anti-CD44 antibody (2 mg ml À1 ) alone for the same time. Cells were then centrifuged by cytospin techniques onto glass sides, stained in MayGrü nwald-Giemsa solution and analysed for cell morphology by means of differential interference contrast microscopy, using a Â 63 objective, or fixed with 4% paraformaldehyde (PFA) and stained with 4,6-diamidino-2-phenylindole (DAPI, Sigma) to visualize the nuclei. Fluorescent images were acquired using a Leica fluorescence microscope with a Â 63 objective (excitation wavelength 350 nm).
Annexin-V FITC analysis
Annexin-V analysis was performed on NB4-LR1 cells treated, as described above, with A3D8 or 8-CPT-cAMP alone, and in cotreatment with 8-CPT-cAMP and A3D8, using the Annexin-V FITC kit from AbCys (France) according to the manufacturer's instructions. Cells were then analysed by flow cytometry on a FACSCalibur instrument (Becton Dickinson Immunocytometry Systems) using CellQuest software. Results were expressed as histograms of FITC staining (fluorescence intensity) and quantified as the relative mean fluorescence intensity. Representative histograms represent an acquisition of 10 4 events.
Results and discussion
Defects in CD44 expression in NB4-LR1 cells
It has been previously shown that A3D8, an anti-CD44 antibody directed against epitope 1, induces typical morphological changes in NB4 cells followed by cell death. 8, 25 By contrast, our data indicated that the maturation-resistant NB4-LR1 subclone failed to respond to A3D8 anti-CD44 signalling. We wanted to elucidate the origin of this defect. One explanation for this unresponsiveness might be that the CD44 gene is silenced in the resistant cells. We therefore analysed comparatively CD44 expression in the parental NB4 cells and in NB4-LR1 cells, at CD44 transcript and protein level.
CD44 transcripts, as evaluated by reverse transcription (RT)-PCR, were strongly expressed in NB4 cells, while, under the same conditions, only a faint signal was detected in NB4-LR1 cells (Figure 1a) . Comparative fluorescence-activated cell sorting (FACS) analyses of NB4 and NB4-LR1 cells (Figure 1b) showed that, in concordance with PCR data for CD44 transcripts, NB4-LR1 cells had hardly detectable CD44 protein expression at the outer plasmatic membrane, while, as expected, the CD44-specific fluorescence profile for NB4 cells showed a marked shift to the right (42 log). Confocal analyses were also performed and confirmed the defective pattern of CD44 expression in NB4-LR1: the lack of surface CD44 expression was due to the absence of CD44 protein synthesis by these cells and did not result from a modified subcellular distribution (Figure 1c) . Altogether, these data clearly demonstrated that the NB4-LR1 unresponsiveness to CD44 was correlated to silencing of the CD44 gene.
DNA hypermethylation and histone deacetylation at promoter of CD44 gene Several mechanisms could explain CD44 gene silencing in NB4-LR1 cells. Analysis of the 1.1 kb CD44 promoter sequence revealed a GC-rich domain (64%) 26, 27 containing four CCGG motifs for HpaII/MspI enzymatic digestion (featured in Figure 2b , bottom). Therefore, genomic DNAs from NB4 and NB4-LR1 cells were digested with either the methylation-insensitive and methylation-sensitive restriction enzymes, MspI and HpaII, respectively, or the McrBC restriction endonuclease known to cleave only methylated DNA. Then, 777 bp DNA stretches (À668 to þ 109 in exon 1, respective to the translation start; see Figure 2b , bottom) were assayed for amplification by PCR. As shown in Figure 2a , the endonuclease cleavage patterns observed are in accordance with DNA methylation of CD44 promoter and/or exon 1 in NB4-LR1, compared to the CD44 promoter in CD44-expressing NB4 cells.
To confirm these results and identify the CpG methylated within the CD44 promoter, pyrosequencing analysis of bisulphite-treated DNA was performed (Figure 2b, top) . This real-time DNA sequencing technology enables to identify methylated cytosine at any single CpG, as well as to quantify the proportion of methylated alleles. Within the CD44 promoter/ exon 1 region, a DNA stretch that harbours 41 CpGs was therefore sequenced and analysed. All CpG sites, except one (CpG 24 ) located in the promoter, were methylated in 75% of alleles of resistant NB4-LR1 cells, including the CpGs of the Sp1/Egr-1 sites (featured in Figure 2b , bottom). In contrast, no methylated CpG was found in the majority (70%) of alleles in parental NB4 cells (Figure 2b, top) .
Post-translation modifications at N-terminal tails of histones are epigenetic events known to have dramatic effects on transcriptional regulation. The importance of histone acetylation in such regulation is now largely accepted: hyperacetylated histones are mainly associated with activated genomic regions, whereas, by contrast, hypoacetylation mainly results in repression and silencing. [28] [29] [30] We therefore wanted to know whether the reported defects in NB4-LR1 cells were associated with Restoration of CD44-mediated cell death by cAMP I Abecassis et al altered acetylation of histones at the CD44 locus. Histone acetylation at the CD44 promoter region was analysed in NB4 and NB4-LR1 cells comparatively, by ChIP experiments using antibodies against acetylated histone H3 and H4. As shown in Figure 2c , CD44 promoter regions are strongly immunoprecipitated with anti-acetylated H3 and H4 antibodies in NB4 cells. In contrast, a very low level of acetylation is found in NB4-LR1 cells for the CD44 promoter. These results suggest that a transcriptionally repressive chromatin characterized by the presence of strongly underacetylated histones is indeed associated with methylated DNA at the CD44 gene promoter, in resistant NB4-LR1 cells.
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Cyclic AMP-induced reversal of CD44 gene silencing
Our data point to a silencing mechanism that leads to the extinction of CD44 gene, normally expressed in parental APL cells. Our previous studies 15, 16, 31 are consistent with the idea that cAMP operates in NB4-LR1 cells by reactivating the expression of genes whose transcription, essential to promyelocytic differentiation program and cell death, has been repressed. We therefore wanted to know whether the expression of CD44 could be reactivated by cAMP signalling (Figure 3) . In NB4 cells, the maturation inducing treatment by ATRA did not significantly increase the already high level of CD44 mRNA, as measured by RT-PCR (Figure 3a) . Similarly, treatment of these cells with 8-CPT-cAMP did not increase further CD44 mRNA. In contrast, in NB4-LR1 cells, a strong upregulation of CD44 was induced by the cAMP analogue in these resistant cells (Figure 3a) . The induction of CD44 mRNA expression by cAMP was detected after 48 h of treatment, with a maximum observed at 72 h (Figure 3b ). CD44 mRNA upregulation was corroborated by CD44 expression at the protein level after 72 h cAMP treatment, as shown by FACS analysis (Figure 3c) . A clear shift 41 log to the right of the mock-or ATRA-treated NB4-LR1 cells was observed, with fluorescence levels that however did not reach those observed in the parental NB4 cells. Furthermore, fluorescence imaging analyses (Figure 3d ) confirmed that the very faint expression level of CD44 in NB4-LR1 was strongly increased in cAMP-treated cells, which became adherent to fibronectin or hyaluronan-coated culture dishes. These pictures indicated that the re-expressed CD44 receptor was clearly localized at the extremity of lamellipodia in polarized adherent NB4-LR1 cells.
Since epigenetic silencing of CD44 involves both DNA methylation and histone deacetylation, we also checked the role of 5-aza-CdR, a well-known DNA methylating inhibitor, as well as the role of the histone deacetylase inhibitor, TSA, on the expression of CD44. Whereas TSA (10 ng ml À1 ) alone did not lead to CD44 gene reactivation (data not shown), 5-aza-CdR, at concentrations as low as 100 nM-induced CD44 re-expression after 72 h of treatment (Figure 3d ). All cells were however not labelled by anti-CD44 antibody and 250 nM 5-aza-CdR was needed to fully re-activate CD44 gene. Restoration of CD44-mediated cell death by cAMP I Abecassis et al treatments in NB4-LR1 cells, we first wanted to determined whether, in fine, these two drugs targeted the CD44 promoter similarly (DNA demethylation).
DNA from the mock-, 5-aza-CdR-and cAMP-treated NB4-LR1 cells were processed for sodium bisulphite pyrosequencing. Up to 41 cytosines in CpG sites of the CD44 promoter were analysed comparatively after 5-aza-CdR and cAMP treatments (Figure 4a ). After 5-aza-CdR treatment, about 20 cytosines, among them those located within transcription factor-binding regions, such as Egr-1/Sp1-binding sites, have lost methylation in more than 30-40% of the alleles sequenced. Furthermore, the CpG sites found in the region immediately upstream the potential transcription initiation sites were significantly demethylated by 5-aza-CdR treatment. It suggests that demethylation of these two regions of the CD44 promoter could well account for the 5-aza-CdR-induced reactivation of the CD44 promoter.
In contrast with the data obtained with 5-aza-CdR, bisulphite pyrosequencing of cAMP-treated NB4-LR1 DNA did not revealed any significant loss of methylation of the cytosines located at either the promoter or exon 1 regions in 100% of the methylated alleles (Figure 4a ).
Histone modifications at CD44 locus. Current hypotheses suggest that histone modifications on the terminal tails, including acetylation, methylation and phosphorylation, constituting a code, are crucial steps in controlling transcription of genes. [32] [33] [34] As mentioned above, in addition to acetylation of lysine residues, histone H3 phosphorylation of Ser10 or phospho-acetylation of Ser10, Lys14 are shown associated with active loci, [35] [36] [37] while methylation of lysine 9 in histone H3 is associated with silent loci. [38] [39] [40] [41] ChIP experiments specifically performed at the CD44 locus with anti-acetyl Lys9;Lys14 (H3AcK9;K14) or anti-phospho-acetyl Ser10;Lys14 (H3pS10AcK14) histone H3 antibodies did not reveal any change in histone H3 tail modifications after cAMP treatment (Figure 4b) . Neither the level of lysine 9 trimethylation was modified by cAMP (not shown). We conclude that cAMP was unable to induce histone tail modifications at CD44 locus specifically.
Histone H3 dual modification on global level. cAMP is known to induce pleiotropic effects in a number of cell lineages. Global modification of chromatin could be the process by which cAMP induces a broad reactivation of gene expression, as illustrated by DNA microarray assays 42 and Pendino (personal communication). Histone H3 dual modification on a global level was investigated in NB4-LR1 cells. As shown in Figure 4c , in bulk chromatin, cAMP was found to upregulate the histone H3pS10AcK14 dual modification. Indeed, western blot analysis, using the same antibody, revealed a 2.5-fold increase in this dual modification, following cAMP treatment of NB4-LR1 cells, while none of the other histone modifications that we examined were changed.
cAMP induces recruitment of c-Jun, Brm and RNA Pol II at CD44 promoter. The above result is of particular interest because it further points at the complexity of cAMP signalling, as a general modifier of tumour cell phenotype, and is consistent with an indirect action of this agent at the CD44 locus to reactivate this gene. cAMP could lead, through the phosphoacetylation of histone H3, to a broad expression of trans-acting factors, 43, 44 enabling their recruitment at specific sites on the CD44 promoter. 45, 46 In particular, our findings are reminiscent of the study by Hyman et al. 45 showing that the transcription factor c-Jun was involved in transcriptional reactivation of the silenced CD44 gene, whereas its promoter is still fully methylated. We further checked whether c-Jun expression is modulated by cAMP in NB4-LR1 cells, and analysed the ability of this transcription factor to bind CD44 promoter. As shown in or 96 h-cAMP ( þ )-treated NB4-LR1 chromatin with anti-AcK9; K14 and anti-pS10AcK14-specific antibodies and amplified using two pairs of primers: A region (1) and B region (2) . The level of enrichment of CD44 regions, relative to the input DNA (total chromatin) and to the control (Pax5 gene), was represented. b2-Microglobulin (3) was used as histone H3 acetylation (AcK9;K14) positive control. (c) Upregulation of histone H3pS10/ AcK14 dual modification by cAMP on a global level was analysed by western blots. Proteins from total lysates of NB4-LR1 cells, treated or not (À) with cAMP ( þ ) for 48 h, were resolved on 10-20% SDS-polyacrylamide gel electrophoresis (PAGE) and processed for immunoblotting with anti-phospho-acetyl ser10;lys14 H3 (pS10AcK14), anti-acetyl-lys14 H3 (AcK14), anti-phospho-ser10 H3 (pS10) and anti-trimethyl-lys9 H3 (trimeK9) antibodies. Corresponding Ponceau-red stains for loading controls were represented. Equal amounts of chromatin from mock-or 48 h-cAMP-treated NB4-LR1 cells were immunoprecipitated (ChIP) with no antibody (control), or specific antibody to Brm (Brm Ab). PCR reactions were carried out using primers within the CD44 promoter (487 bp product). PCRs with input chromatin were shown as positive control. A region of the GAPDH promoter was amplified as background control (GAPDH). (d) ChIP assay for interaction of RNA PoI II within the CD44 proximal promoter region. Equal amounts of chromatin from mock-or 48 h-cAMP-treated NB4-LR1 cells were immunoprecipitated (ChIP) with no antibody (control), or anti-RNA Pol II (RNA Pol II Ab). PCR reactions were carried out using primers encompassing the transcription start region (297 bp product). PCRs with input chromatin were shown as positive control. Negative primers served as background control (negative control).
Restoration of CD44-mediated cell death by cAMP I Abecassis et al PCR, using primers specific for a region of CD44 promoter encompassing the AP-1 site (À278/À164). As shown in Figure 5c , c-Jun interacts with the CD44 promoter in 48 h-cAMP-treated NB4-LR1 cells, but not in the absence of treatment, or in 24 h-treated cells (data not shown). It is interesting to note that the cytosine at position À250, located just upstream from the AP-1 site, is found unmethylated by pyrosequencing in 70% of the alleles in NB4-LR1 cells, treated or not by cAMP (see in Figures 2b and 4a) .
The human SWI/SNF subunit brahma (Brm) is known to be a chromatin-remodelling factor. It has been recently described to contribute to the crosstalk between transcription and RNA Pol II processing and to be directly involved in the re-activation of CD44 in a carcinoma cell line where CD44 transcription was silenced by hypermethylation of CpG island within its promoter. 46, 47 In NB4-LR1 cells, Brm is expressed at transcriptional and protein levels (Figures 6a and b) , without modulation of its expression by cAMP. ChIP assays reveal that, in 48 h-cAMPtreated cells, Brm protein interacts with CD44 promoter, whereas no interaction is detectable in untreated cells (Figure 6c ). Binding of phosphorylated RNA Pol II to the proximal promoter region of CD44, encompassing the transcription start site, is also observed in the same chromatin samples, whereas RNA Pol II is poorly paused at the promoter region of the inactive CD44 gene in absence of 8-CPT-cAMP treatment (Figure 6d) .
Altogether, our results suggest that, in NB4-LR1 cells, cAMP leads to the recruitment of trans-acting factors at the CD44 promoter, to the re-expression of CD44 gene and CD44 receptor, then, ultimately, to a functional CD44 signalling pathway. To check this hypothesis, we wish to determine whether cAMP could restore a CD44-dependent cell death response in these cells.
Cell death induction by A3D8 anti-CD44 antibody in cAMP-induced CD44 re-expressing NB4-LR1 cells
As mentioned previously, A3D8 anti-CD44 antibody has been described to induce death of myeloid leukaemia cells including the NB4 APL cells. 8, 25 We therefore examined whether, in resistant cells, the cAMP-dependent re-expression of CD44 at the cell surface generated a functional receptor responsive to A3D8 anti-CD44 antibody signalling. Cyclic-AMP treatment alone rapidly leads to NB4-LR1 cell growth inhibition. As illustrated in Figure 6a , the round blast cells became smaller and polarized after cAMP treatment and were further characterized by the formation of pseudopodia at one extremity. The A3D8 anti-CD44 antibody alone did not significantly change the myeloblastic morphology of cells, although they became moderately larger, a slight effect that could be due to a faint but detectable CD44 gene expression leakage (as reported in Figure 1a ). Unambiguously, co-treatment of cells with cAMP and A3D8 antibody induced marked morphological changes, both at the membrane and nuclear levels, typical of apoptotic cells. By means of differential interference contrast imaging, numerous blebbing-like protrusions at the cell surface, as well as nuclear membrane remodelling, were observed (Figure 7a ). Also nuclei completely lost their round homogenous appearance and presented profound modifications before cell structures were finally dismantled. DAPI staining of the nuclei further showed a chromatin gathering at the periphery of the nucleus or a fragmented morphology of nuclear bodies (Figure 7b ). In concordance with these data, FACS analysis of Annexin-V expression, a marker of apoptosis, showed a significant positive staining of NB4-LR1 cells co-treated with 8-CPT-cAMP and A3D8 (Figure 7c) , with a fluorescence profile comparable to that observed in A3D8-treated parental NB4 cells (data not shown).
The slight effect observed with A3D8 alone could be due, as mentioned above, to the faint basal expression of CD44 in these cells. These results demonstrate that cAMP induces the expression of a functional CD44 receptor at the surface of resistant cells, which is able to trigger cell death signalling induced by the A3D8 antibody, as in NB4 APL cells.
Conclusion
Here, we report for the first time that the ATRA-maturationresistant NB4-LR1 cells are additionally resistant to CD44-dependent cell death. The molecular bases of the CD44-death unresponsiveness and its rescue have been deciphered:
(1) These cells are deficient in the expression of CD44 (Figure 1 ), an adhesion and signalling receptor known to be a key actor in the maturation of myeloid progenitors. 48 (2) The defect involves alterations in DNA and chromatin structure, that is, hypermethylation of the 5 0 -region CpG island and de-acetylation of histones associated with the promoter site of the CD44 gene, two epigenetic mechanisms, which could be responsible for CD44 gene repression. This result is supported by the finding that the methylating inhibitor 5-aza-CdR restores CD44 expression and this re-activation is associated with partial demethylation of the promoter (Figure 4a ). (3) cAMP, like the demethylating agent 5-aza-CdR, restores transcriptional competence of the highly methylated CD44 gene, but importantly it occurred despite that the CD44 promoter remained highly methylated. (4) cAMP signalling could favour broad chromatin changes (H3 dual modification H3pS10AcK14) and transcription patterns (c-Jun, CD44), benefiting anti-tumour signalling (cell death).
This work has revealed a new and unique phenotypic feature of NB4-LR1 cells: a double (ATRA-maturation and CD44-dependent death) resistant cell line, whose defects in the triggering of two distinct biological responses are cured by the same signal (cAMP). As we reported earlier, NB4-LR1 cells show defects in this crosstalk and pharmacological cAMP signalling is necessary for retinoid induction of maturation. [14] [15] [16] At present, little is known about the role of cAMP and its crosstalk with retinoids to induce the maturation and the apoptosis of APL. The mechanisms by which cAMP acts seem to be complex and may involve different signalling pathways and targets, including targeting transcription effectors, such as CREB, CBP300, PML-RARa or RXR receptors by direct or indirect phosphorylation, [18] [19] [20] 49 or changes in nuclear bodies 17, 50 or late and indirect re-expression of a large list of genes, 43, 51, 52 including c-Jun and CD44. Given the reported features shared by cAMP/retinoid (cell maturation) and cAMP/CD44 (cell death) cooperation, namely, the biological and biochemical effects are late and need a sustained signalling to develop, it is more clear that the mechanisms involved do not depend on a discrete set of cAMP/PKA targets, but rather result from a broad transcriptional reprogrammation of a multi-resistant tumour cell.
More specifically, the finding of a new cooperation pathway, that is, cAMP/anti-CD44 co-signalling, which is able to induce death of an otherwise maturation-resistant tumour cell, could be of prime importance for the development of new combination therapies in resistant APL.
